



Santa Clara
Family Health Plan
The Spirit of Care

To: Providers
From: Jeff Robertson, Chief Medical Officer
Date: July 12, 2017
Subject: **Medi-Cal & HK Formulary Changes: Added Basaglar; Removed Lantus**

Dear Providers:

Santa Clara Family Health Plan's (SCFHP) Pharmacy and Therapeutics Committee recently conducted a therapeutic class review of long-acting insulins. Based on the review, Basaglar KwikPen-U100 was added to ensure coverage for safe, clinically-equivalent, and cost-effective medications. Clinical studies have shown that Basaglar KwikPen (insulin glargine) provides similar efficacy when compared with other long-acting insulins.

Please consider the preferred agent, **Basaglar KwikPen (insulin glargine)**, as a formulary alternative for your patients.

Effective September 1, 2017, Lantus (insulin glargine) vial and Lantus Solostar insulin pens will no longer be covered without prior authorization for Medi-Cal and Healthy Kids. Members who currently have a prescription claim for Lantus or Lantus Solostar will receive a letter describing this formulary change. The letter will advise members to continue using the medication until they have consulted their physician.

If you have any questions about this formulary change, contact SCFHP's Pharmacy Department at 1-408-874-1796.

Thank you for your continuing care of our members.